Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Qiagen will develop, manufacture, market a molecular companion diagnostic for Eli Lilly and company's JAK2 inhibitor.
Subscribe to our email newsletter
JAK2 inhibitor, is Lilly’s early stage investigational proprietarycompound, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms.
The new companion diagnostic test provides both qualitative and quantitative results for use of the JAK2 V617F during clinical trials.
Qiagen said that the new PCR-based companion diagnostic will be marketed and will run on its Rotor-Gene Q instrument.
Qiagen Personalized Healthcare vice president Stephen Little said the company aims to develop potential for the diagnostic-therapeutic combination to improve the standard of care for patients suffering from blood cancers.